

## Türkiye Sigorta (TURSG TI)

## **Buy: Another Goldilocks year**

- Accommodative regulatory backdrop and mix shift improving operating margins; high rates boosting financial income
- We expect earnings to double in 2024e (prev +35%); 2024e
  PE of 3.8x is still close to the bottom of the range
- Buy; lift TP to TRY59.50 (from TRY34.00) on higher earnings; shares look undervalued despite strong performance in 2023

Shares have yet to price in robust earnings outlook for 2024: We raise our FY24e and FY25e earnings for Türkiye Sigorta by 58% and 72%, respectively, given: 1) a faster shift away from loss-making traffic policies; 2) favourable regulatory changes; and 3) higher returns on the investment portfolio. Our FY24e earnings of TRY13bn correspond to 106% YoY growth and are 25% above BBG consensus. Moreover, they imply a 2024e PE of 3.8x, which is close to the bottom of the last three-year trading range, notwithstanding the stock's c225% appreciation in 2023. Owing to strong earnings momentum, potential for consensus earnings upgrades and an attractive valuation, we raise our TP by 75% to TRY59.50 (from TRY34.00) and reiterate our Buy rating. We expect the stock to come on to the radar of foreign investors in 2024, with more frequent company attendance at investor events abroad.

**Decisive reduction in MTPL market share is helping operational profitability:** We expect the combined ratio to stay at 100% in FY24, with risks to the positive side as: 1) the company gradually substitutes loss making MTPL (motor third-party liability) business with profitable MOD (motor own damage); 2) slower growth in MTPL could release some unexpired risks reserves; 3) recent increase in the regulatory price cap for MTPL policies should alleviate losses in the segment; 4) real appreciation of the currency could help with claims inflation in the motor segment, where spare parts are mostly imported; and 5) the regulator may increase the discount rate (currently 28%) used in actuarial calculations, which could result in provision releases. Note that Türkiye Sigorta's combined ratio is below 100% in all segments except for MTPL (Figure 4).

**Investment income boost amid high interest rates:** As of 3Q23, Türkiye Sigorta's investment portfolio was generating TRY1bn income per month. Allowing for higher interest rates, compounding of the portfolio and further growth from new business underwriting, FY24e investment income should be ahead of TRY12bn. Moreover, our 100% combined ratio projection (ie, breakeven at the operational level) means that investment income will trickle down to the bottom line. As such, we expect Türkiye Sigorta to report TRY13bn earnings in FY24e, 106% above last year.

**Shares look undervalued despite re-rating:** Türkiye Sigorta's share price more than tripled last year, but its 12m forward PE multiple is still a very undemanding 3.8x for its robust earnings growth. Figure 6 shows that Türkiye Sigorta's valuation hasn't fallen below 6.0x on a sustainable basis since 2020.

## **Disclosures & Disclaimer**

This report must be read with the disclosures and the analyst certifications in the Disclosure appendix, and with the Disclaimer, which forms part of it.

## Equities Insurance


## Türkiye

TARGET PRICE (TRY)		PREVIOUS TAP <b>34.00</b>	RGET (TRY)				
SHARE PRICE (TRY) 42.20 (as of 02 Jan 2024)		UPSIDE/DOWN +41.09					
MARKET DATA Market cap (TRYm)	49,016	Free float	19%				
Market cap (USDm) 3m ADTV (USDm)	1,649 7	BBG RIC	TURSG TI TURSG.IS				

#### FINANCIALS AND RATIOS (TRY)

Year to	12/2022a	12/2023e	12/2024e	12/2025e					
IFRS EPS	0.81	5.39	11.11	14.38					
IFRS EPS (prev)	0.81	5.18	7.02	8.34					
Change (%)	0.0	4.1	58.4	72.3					
Consensus EPS	0.95	5.36	7.46	8.41					
PE (x)	52.1	7.8	3.8	2.9					
Dividend yield (%)	1.1	0.3	2.6	5.3					

#### 52-WEEK PRICE (TRY)



Source: Refinitiv IBES, HSBC estimates

#### Cihan Saraoglu\*, PhD

Türkiye & Greece Banks Analyst HSBC Yatirim Menkul Degerler A.S. cihansaraoglu@hsbc.com.tr +90 212 376 46 20

#### Siddarth Sambamurthy\* Associate

Bangalore

\* Employed by a non-US affiliate of HSBC Securities (USA) Inc, and is not registered/ qualified pursuant to FINRA regulations

## Waiting in the wings

The 14<sup>th</sup> edition of the EM Sentiment Survey

Click to view

**Issuer of report:** HSBC Yatirim Menkul Degerler AS

https://www.research.hsbc.com



## Buy

12/2022a

6

0

n/a

33.3

## Financials & valuation: Türkiye Sigorta

#### **Financial statements**

P&L summary (TRYm)        Earned premiums      6,893      22,221        GWP      25,173      55,765        Losses incurred (-)      7,263      17,736        Opex (-)      1,909      4,889        Others      110      260        Net technical income      -2,169      -144        Investment income      3,199      8,424        Others      235      -450        PBT      1,266      7,829        Taxes (-)      324      1,566        NI      941      6,263        Balance sheet summary (TRYm)      26,241        Investments      11,753      23,148        Subsidiaries      3,040      3,040	39,761 94,215 30,576 9,145 310 350 17,108 -250 17,208 4,302	57,972 137,366 44,599 13,334 360 400 22,117 -250 22,267 5,567
GWP      25,173      55,765        Losses incurred (-)      7,263      17,736        Opex (-)      1,909      4,889        Others      110      260        Net technical income      -2,169      -144        Investment income      3,199      8,424        Others      235      -450        PBT      1,266      7,829        Taxes (-)      324      1,566        NI      941      6,263        Balance sheet summary (TRYm)      26,241        Investments      11,753      23,148        Subsidiaries      3,040      3,040	94,215 30,576 9,145 310 350 17,108 -250 17,208	137,366 44,599 13,334 360 400 22,117 -250 22,267
Losses incurred (-)      7,263      17,736        Opex (-)      1,909      4,889        Others      110      260        Net technical income      -2,169      -144        Investment income      3,199      8,424        Others      235      -450        PBT      1,266      7,829        Taxes (-)      324      1,566        NI      941      6,263        Balance sheet summary (TRYm)      26,241        Investments      11,753      23,148        Subsidiaries      3,040      3,040	30,576 9,145 310 350 17,108 -250 17,208	44,599 13,334 360 400 22,117 -250 22,267
Opex (-)      1,909      4,889        Others      110      260        Net technical income      -2,169      -144        Investment income      3,199      8,424        Others      235      -450        PBT      1,266      7,829        Taxes (-)      324      1,566        NI      941      6,263        Balance sheet summary (TRYm)      U      U        Cash and banks      9,034      26,241        Investments      11,753      23,148        Subsidiaries      3,040      3,040	9,145 310 350 17,108 -250 17,208	13,334 360 400 22,117 -250 22,267
Others      110      260        Net technical income      -2,169      -144        Investment income      3,199      8,424        Others      235      -450        PBT      1,266      7,829        Taxes (-)      324      1,566        NI      941      6,263        Balance sheet summary (TRYm)      26,241        Investments      11,753      23,148        Subsidiaries      3,040      3,040	310 350 17,108 -250 17,208	360 400 22,117 -250 22,267
Net technical income      -2,169      -144        Investment income      3,199      8,424        Others      235      -450        PBT      1,266      7,829        Taxes (-)      324      1,566        NI      941      6,263        Balance sheet summary (TRYm)      2      26,241        Investments      11,753      23,148        Subsidiaries      3,040      3,040	350 17,108 -250 17,208	400 22,117 -250 22,267
Investment income      3,199      8,424        Others      235      -450        PBT      1,266      7,829        Taxes (-)      324      1,566        NI      941      6,263        Balance sheet summary (TRYm)      26,241        Investments      11,753      23,148        Subsidiaries      3,040      3,040	17,108 -250 17,208	22,117 -250 22,267
Others      235      -450        PBT      1,266      7,829        Taxes (-)      324      1,566        NI      941      6,263        Balance sheet summary (TRYm)      2      2        Cash and banks      9,034      26,241        Investments      11,753      23,148        Subsidiaries      3,040      3,040	-250 17,208	-250 22,267
PBT      1,266      7,829        Taxes (-)      324      1,566        NI      941      6,263        Balance sheet summary (TRYm)      2      2        Cash and banks      9,034      26,241        Investments      11,753      23,148        Subsidiaries      3,040      3,040	17,208	22,267
Taxes (-)      324      1,566        NI      941      6,263        Balance sheet summary (TRYm)      9      26,241        Investments      11,753      23,148        Subsidiaries      3,040      3,040	,	
NI      941      6,263        Balance sheet summary (TRYm)      6,263        Cash and banks      9,034      26,241        Investments      11,753      23,148        Subsidiaries      3,040      3,040	4 302	5 567
Balance sheet summary (TRYm)        Cash and banks      9,034      26,241        Investments      11,753      23,148        Subsidiaries      3,040      3,040	4,002	5,507
Cash and banks      9,034      26,241        Investments      11,753      23,148        Subsidiaries      3,040      3,040	12,906	16,700
Investments      11,753      23,148        Subsidiaries      3,040      3,040		
Subsidiaries 3,040 3,040	23,153	41,767
	24,820	26,469
	4,712	6,362
Receivables 4,546 10,071	17,014	24,807
Others 2,865 5,335	8,242	11,504
Total assets 28,199 64,794	73,229	104,547
Payables 3,336 3,000	5,069	7,390
Technical provisions 14,923 27,824	37,997	52,834
Others 1,316 2,700	2,700	2,700
Total liabilities 21,778 51,367	48,148	65,347
Equity 6,421 13,427	25,081	39,199

## Ratios & growth

Year to	12/2022a	12/2023e	12/2024e	12/2025e
Y-o-y % change				
Earned premiums	68%	222%	79%	46%
GWP	114%	122%	69%	46%
Net technical income	n.m.	n.m.	n.m.	14%.
Investment income	123%	163%	103%	29%
PBT	-10%	519%	120%	29%
NI	-11%	565%	106%	29%
Cash and banks	48%	190%	-12%	80%
Investments	227%	97%	7%	7%
Ratios (%)				
Retention ratio	51%	58%	60%	60%
Dividend payout ratio	50%	17%	20%	20%
Combined ratio	131%	102%	100%	100%
Loss ratio	104%	80%	77%	77%
Expense ratio	28%	22%	23%	23%

## Per share data (TRY)

Year to	12/2022a	12/2023e	12/2024e	12/2025e
EPS reported (diluted)	0.81	5.39	11.11	14.38
HSBC EPS (diluted)	0.81	5.39	11.11	14.38
DPS	0.46	0.13	1.08	2.22
NAV	5.53	11.56	21.59	33.75

#### Valuation data

Year to	12/2022a	12/2023e	12/2024e	12/2025e
PE reported*	52.1	7.8	3.8	2.9
PE (HSBC)*	52.1	7.8	3.8	2.9
Price / NAV	7.6	3.7	2.0	1.3
Dividend yield (%)	1.1	0.3	2.6	5.3
Reported ROE	18%	63%	67%	52%
*D 1 19 1 1 1				

\* Based on diluted shares

## ESG metrics

Environmental Indicators	12/2022a	Governance Indicators
GHG emission intensity*	4.4	No. of board members
Energy intensity*	14.4	Average board tenure (years)
CO <sub>2</sub> reduction policy	Yes	Female board members (%)
Social Indicators	12/2022a	Board members independence (%)
Employee costs as % of revenues	n/a	
Employee turnover (%)	9.9	
Diversity policy	Yes	


Source: Company data, HSBC

\* GHG intensity and energy intensity are measured in kg and kWh respectively against revenue in USD '000s

## **Issuer information**

Share price (TRY)	42.20	Free float	19%
Target price (TRY)	59.50	Sector	Insurance
RIC (Equity)	TURSG.IS	Country/Region	Türkiye
Bloomberg (Equity)	TURSG TI	Analyst	Cihan Saraoglu, PhD
Market cap (USDm)	1,649	Contact	+90 212 376 46 20


### **Price relative**



Source: HSBC


Note: Priced at close of 02 Jan 2024






1: Strong AUM growth and high interest rates

2: ...boosting Türkiye Sigorta's financial income




Source: Company data, HSBC calculations, \* latest TRY time deposit rate for 9M23 vs averages for previous periods

3: GWP mix gradually shifting away from lossmaking MTPL products to...




Source: TIA

5: ...as recent increase in cap rates should improve pricing significantly in 1Q24



Source: TIA, HSBC calculations

4: ...better margin MOD products. Meanwhile, losses in MTPL are likely to decrease further....



Source: Company data. Notes: F&ND stands for fire and natural disaster; MTPL stands for mandatory third party liability; MOD stands for motor own damage

#### 6: Stock is still trading at c4x PE for 2024



Source: Refinitiv DataStream, HSBC estimates



## Türkiye Sigorta: Income statement – HSBC estimate revisions

		Esti	mates			YoY gi	rowth			Revisions	
(TRYm)	2022a	2023e	2024e	2025e	2022a	2023e	2024e	2025e	2023e	2024e	2025e
Earned premiums	6,893	22,221	39,761	57,972	68%	222%	79%	46%	16%	23%	19%
GWP	25,173	55,765	94,215	137,366	114%	122%	69%	46%	2%	3%	-1%
Losses incurred (-)	7,263	17,736	30,576	44,599	133%	144%	72%	46%	12%	19%	15%
Opex (-)	1,909	4,889	9,145	13,334	93%	156%	87%	16%	13%	9%	9%
Others	110	260	310	360							
Net technical inc.	-2,169	-144	350	400	n.m.	n.m.	n.m.	14%	-82%	-124%	-117%
Investment income	3,199	8,424	17,108	22,117	123%	163%	103%	29%	-8%	35%	42%
o/w financial assets	1,738	3,336	13,979	18,670							
o/w subsidiaries	562	50	78	105							
Others	235	-450	-250	-250							
PBT	1,266	7,829	17,208	22,267	-10%	519%	120%	29%	-2%	58%	72%
Taxes (-)	324	1,566	4,302	5,567							
NI	941	6,263	12,906	16,700	-11%	565%	106%	29%	4%	58%	72%
Market share	12.0%	13.8%	13.8%	13.8%	-144bps	183bps	0bps	0bps	150bps	150bps	150bps
Retention ratio	51%	58%	60%	60%	8pp	7pp	2pp	0pp	4pp	6pp	6pp
Combined ratio	131%	102%	100%	100%	35pp	-29pp	-2pp	0pp	-3pp	-5pp	-5pp
Source: Company data HSB	C estimates										

Source: Company data, HSBC estimates

## Valuation and risks

		Valuation	Risks to our view
Türkiye Sigorta TURSG TI Buy	Current price: TRY42.20 Target price: TRY59.50 Up/downside: 41.0%	We derive our target price from an economic profit model where we: (1) multiply the difference between ROE and COE for every year by that year's core tangible equity; (2) discount yearly economic profit and the terminal value to today; and (3) add them to the last reported core tangible equity. We then add the fair value of the subsidiaries in the latest results after applying a 10% discount to be conservative (unchanged).	<b>Downside risks include</b> : (1) drop in deposit rates; (2) growing share of motor vehicle branches in the premium mix, which could lead to lower technical margins; and (3) transfer pricing. Türkiye Sigorta relies heavily on state bank networks for distribution, which could give banks' pricing power when it comes to the commissions they charge.
		Our COE beyond 2025e until the end of our valuation horizon incorporates a 21% risk-free rate (previously 3.5%), a 5.5% equity risk premium (previously 9.0%), and a beta of 1.0, which implies a cost of equity of 26.5% (unchanged). For 2023e and 2024e, we add to the assumptions an adjustment factor of 13.5% to account for CBRT's monetary tightening amid high inflation. That brings our COE for both years to 40% (previously 26.5%). We update our assumptions to bring our valuation method in line with our bank valuations. We raise our TP to TRY59.50 (from TRY34.00) on higher	

Priced at 02 Jan 2024 Source: HSBC estimates



# **Disclosure appendix**

## **Analyst Certification**

The following analyst(s), economist(s), or strategist(s) who is(are) primarily responsible for this report, including any analyst(s) whose name(s) appear(s) as author of an individual section or sections of the report and any analyst(s) named as the covering analyst(s) of a subsidiary company in a sum-of-the-parts valuation certifies(y) that the opinion(s) on the subject security(ies) or issuer(s), any views or forecasts expressed in the section(s) of which such individual(s) is(are) named as author(s), and any other views or forecasts expressed herein, including any views expressed on the back page of the research report, accurately reflect their personal view(s) and that no part of their compensation was, is or will be directly or indirectly related to the specific recommendation(s) or views contained in this research report: Cihan Saraoglu, PhD.

## Important disclosures

## Equities: Stock ratings and basis for financial analysis

HSBC and its affiliates, including the issuer of this report ("HSBC") believes an investor's decision to buy or sell a stock should depend on individual circumstances such as the investor's existing holdings, risk tolerance and other considerations and that investors utilise various disciplines and investment horizons when making investment decisions. Ratings should not be used or relied on in isolation as investment advice. Different securities firms use a variety of ratings terms as well as different rating systems to describe their recommendations and therefore investors should carefully read the definitions of the ratings used in each research report. Further, investors should carefully read the entire research report and not infer its contents from the rating because research reports contain more complete information concerning the analysts' views and the basis for the rating.

## From 23rd March 2015 HSBC has assigned ratings on the following basis:

The target price is based on the analyst's assessment of the stock's actual current value, although we expect it to take six to 12 months for the market price to reflect this. When the target price is more than 20% above the current share price, the stock will be classified as a Buy; when it is between 5% and 20% above the current share price, the stock may be classified as a Buy or a Hold; when it is between 5% above the current share price, the stock will be classified as a Hold; when it is between 5% above the current share price, the stock will be classified as a Hold; when it is between 5% and 20% below the current share price, the stock may be classified as a Hold; when it is more than 20% below the current share price, the stock may be classified as a Hold or a Reduce; and when it is more than 20% below the current share price, the stock will be classified as a Reduce.

Our ratings are re-calibrated against these bands at the time of any 'material change' (initiation or resumption of coverage, change in target price or estimates).

Upside/Downside is the percentage difference between the target price and the share price.

## Prior to this date, HSBC's rating structure was applied on the following basis:

For each stock we set a required rate of return calculated from the cost of equity for that stock's domestic or, as appropriate, regional market established by our strategy team. The target price for a stock represented the value the analyst expected the stock to reach over our performance horizon. The performance horizon was 12 months. For a stock to be classified as Overweight, the potential return, which equals the percentage difference between the current share price and the target price, including the forecast dividend yield when indicated, had to exceed the required return by at least 5 percentage points over the succeeding 12 months (or 10 percentage points for a stock classified as Volatile\*). For a stock to be classified as Underweight, the stock was expected to underperform its required return by at least 5 percentage points over the succeeding 12 months (or 10 percentage points). Stocks between these bands were classified as Neutral.

\*A stock was classified as volatile if its historical volatility had exceeded 40%, if the stock had been listed for less than 12 months (unless it was in an industry or sector where volatility is low) or if the analyst expected significant volatility. However, stocks which we did not consider volatile may in fact also have behaved in such a way. Historical volatility was defined as the past month's average of the daily 365-day moving average volatilities. In order to avoid misleadingly frequent changes in rating, however, volatility had to move 2.5 percentage points past the 40% benchmark in either direction for a stock's status to change.



#### Rating distribution for long-term investment opportunities

As of 30 September 2023, the distribution of all independent ratings published by HSBC is as follows:					
Buy	58%	(14% of these provided with Investment Banking Services in the past 12 months)			
Hold	36%	(14% of these provided with Investment Banking Services in the past 12 months)			
Sell	7%	(11% of these provided with Investment Banking Services in the past 12 months)			


For the purposes of the distribution above the following mapping structure is used during the transition from the previous to current rating models: under our previous model, Overweight = Buy, Neutral = Hold and Underweight = Sell; under our current model Buy = Buy, Hold = Hold and Reduce = Sell. For rating definitions under both models, please see "Stock ratings and basis for financial analysis" above.

For the distribution of non-independent ratings published by HSBC, please see the disclosure page available at <u>http://www.hsbcnet.com/gbm/financial-regulation/investment-recommendations-disclosures</u>.

#### Share price and rating changes for long-term investment opportunities

## Türkiye Sigorta (TURSG.IS) share price performance

**TRY Vs HSBC rating history** 



#### From Date Analyst То 08 Sep 2021 N/A Buy Cihan Saraoglu Buy Hold 21 Dec 2022 Cihan Saraoglu Hold Buy 14 Mar 2023 Cihan Saraoglu Target price Value Date Analyst 7.60 Price 1 08 Sep 2021 Cihan Saraoglu Price 2 7.90 13 Jun 2022 Cihan Saraoglu Price 3 13.65 21 Dec 2022 Cihan Saraoglu Price 4 16 70 18 Jul 2023 Cihan Saraoglu

24 Aug 2023

Cihan Saraoglu

34.00

Rating & target price history

Source: HSBC

To view a list of all the independent fundamental ratings disseminated by HSBC during the preceding 12-month period, please use the following links to access the disclosure page:

Price 5

Source: HSBC

Clients of HSBC Private Banking: www.research.privatebank.hsbc.com/Disclosures

All other clients: www.research.hsbc.com/A/Disclosures

#### HSBC & Analyst disclosures Disclosure checklist

Company	Ticker	Recent price	Price date	Disclosure
TURKIYE SIGORTA	TURSG.IS	42.20	02 Jan 2024	4,7

Source: HSBC

- 1 HSBC has managed or co-managed a public offering of securities for this company within the past 12 months.
- 2 HSBC expects to receive or intends to seek compensation for investment banking services from this company in the next 3 months.
- 3 At the time of publication of this report, HSBC Securities (USA) Inc. is a Market Maker in securities issued by this company.
- 4 As of 30 November 2023, HSBC beneficially owned 1% or more of a class of common equity securities of this company.
- 5 As of 30 November 2023, this company was a client of HSBC or had during the preceding 12 month period been a client of and/or paid compensation to HSBC in respect of investment banking services.
- 6 As of 30 November 2023, this company was a client of HSBC or had during the preceding 12 month period been a client of and/or paid compensation to HSBC in respect of non-investment banking securities-related services.
- 7 As of 30 November 2023, this company was a client of HSBC or had during the preceding 12 month period been a client of and/or paid compensation to HSBC in respect of non-securities services.



- 8 A covering analyst/s has received compensation from this company in the past 12 months.
- 9 A covering analyst/s or a member of his/her household has a financial interest in the securities of this company, as detailed below.
- 10 A covering analyst/s or a member of his/her household is an officer, director or supervisory board member of this company, as detailed below.
- 11 At the time of publication of this report, HSBC is a non-US Market Maker in securities issued by this company and/or in securities in respect of this company.
- 12 As of 29 December 2023, HSBC beneficially held a net long position of more than 0.5% of this company's total issued share capital, calculated according to the SSR methodology.
- 13 As of 29 December 2023, HSBC beneficially held a net short position of more than 0.5% of this company's total issued share capital, calculated according to the SSR methodology.
- 14 HSBC Qianhai Securities Limited holds 1% or more of a class of common equity securities of this company.

HSBC and its affiliates will from time to time sell to and buy from customers the securities/instruments, both equity and debt (including derivatives) of companies covered in HSBC Research on a principal or agency basis or act as a market maker or liquidity provider in the securities/instruments mentioned in this report.

Analysts, economists, and strategists are paid in part by reference to the profitability of HSBC which includes investment banking, sales & trading, and principal trading revenues.

Whether, or in what time frame, an update of this analysis will be published is not determined in advance.

Non-U.S. analysts may not be associated persons of HSBC Securities (USA) Inc, and therefore may not be subject to FINRA Rule 2241 or FINRA Rule 2242 restrictions on communications with the subject company, public appearances and trading securities held by the analysts.

Economic sanctions laws imposed by certain jurisdictions such as the US, the EU, the UK, and others, may prohibit persons subject to those laws from making certain types of investments, including by transacting or dealing in securities of particular issuers, sectors, or regions. This report does not constitute advice in relation to any such laws and should not be construed as an inducement to transact in securities in breach of such laws.

For disclosures in respect of any company mentioned in this report, please see the most recently published report on that company available at <u>www.hsbcnet.com/research</u>. HSBC Private Banking clients should contact their Relationship Manager for queries regarding other research reports. In order to find out more about the proprietary models used to produce this report, please contact the authoring analyst.

## Additional disclosures

- 1 This report is dated as at 04 January 2024.
- 2 All market data included in this report are dated as at close 02 January 2024, unless a different date and/or a specific time of day is indicated in the report.
- 3 HSBC has procedures in place to identify and manage any potential conflicts of interest that arise in connection with its Research business. HSBC's analysts and its other staff who are involved in the preparation and dissemination of Research operate and have a management reporting line independent of HSBC's Investment Banking business. Information Barrier procedures are in place between the Investment Banking, Principal Trading, and Research businesses to ensure that any confidential and/or price sensitive information is handled in an appropriate manner.
- 4 You are not permitted to use, for reference, any data in this document for the purpose of (i) determining the interest payable, or other sums due, under loan agreements or under other financial contracts or instruments, (ii) determining the price at which a financial instrument may be bought or sold or traded or redeemed, or the value of a financial instrument, and/or (iii) measuring the performance of a financial instrument or of an investment fund.

#### **Production & distribution disclosures**

- 1. This report was produced and signed off by the author on 03 Jan 2024 17:29 GMT.
- 2. In order to see when this report was first disseminated please see the disclosure page available at https://www.research.hsbc.com/R/34/vVQzBbp



## Disclaimer

Legal entities as at 30 June 2023:

<sup>1</sup>UAE' HSBC Bank Middle East Limited, DIFC; HSBC Bank Middle East Limited, UAE branch; <sup>1</sup>HK' The Hongkong and Shanghai Banking Corporation Limited, Hong Kong; <sup>1</sup>TW' HSBC Securities (Taiwan) Corporation Limited; <sup>1</sup>CA' HSBC Securities (Canada) Inc.; <sup>1</sup>France' HSBC Continental Europe; <sup>1</sup>Spain' HSBC Continental Europe, Sucursal en España; <sup>1</sup>Italy' HSBC Continental Europe, Italy; <sup>1</sup>Sweden' HSBC Continental Europe Bank, Sweden Filial; <sup>1</sup>DE' HSBC Continental Europe SA, Germany; 000 HSBC Bank (RR), Moscow; <sup>1</sup>N' HSBC Securities and Capital Markets (India) Private Limited, Mumbai; <sup>1</sup>JP' HSBC Securities (Japan) Limited, Tokyo; <sup>1</sup>EG' HSBC Securities Egypt SAE, Cairo; <sup>1</sup>CN' HSBC Investment Bank Asia Limited, Beijing Representative Office; The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch; The Hongkong and Shanghai Banking Corporation Limited, Secul Securities Branch; The Hongkong and Shanghai Banking Corporation Limited, Securities (USA) Inc., New York; HSBC Yatirim Menkul Degerler AS, Istanbul; HSBC México, SA, Institución de Banca Múltiple, Grupo Financiero HSBC; HSBC Bank Australia Limited; HSBC Bank Argentina SA; HSBC Saudi Arabia Limited; The Hongkong and Shanghai Banking Corporation Limited, New Zealand Branch incorporated in Hong Kong SAR; The Hongkong and Shanghai Banking Corporation Limited, Bangkok Branch; PT Bank HSBC Indonesia; HSBC Qianhai Securities Limited; Banco HSBC SA

Issuer of report HSBC Yatirim Menkul Degerler AS Buyukdere Caddesi No: 122 / D Kat:9 Esentepe/Sisli 34394 Istanbul, Türkiye Telephone: +90 212 376 46 00 Fax: +90 212 376 49 13 www.research.hsbc.com www.hsbcyatirim.com.tr

This document has been issued by HSBC Yatırım Menkul Degerler A.S. (HSBC) for the information of its customers only. If it is received by a customer of an affiliate of HSBC, its provision to the recipient is subject to the terms of business in place between the recipient and such affiliate.

HSBC has based this document on information obtained from sources it believes to be reliable but which it has not independently verified; HSBC makes no guarantee, representation or warranty and accepts no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of the Research Department of HSBC only and are subject to change without notice. From time to time research analysts conduct site visits of covered issuers. HSBC policies prohibit research analysts from accepting payment or reimbursement for travel expenses from the issuer for such visits. The investment information, comments and advice given herein are not part of investment advice activity. Investment advice services are provided by authorized institutions to persons and entities privately by considering their risk and return preferences, whereas the comments and advice included herein are of a general nature. Therefore, they may not fit your financial situation and risk and return preferences. For this reason, making an investment decision only by relying on the information given herein may not give rise to results that fit your expectations.

HSBC and its affiliates and/or their officers, directors and employees may have positions in any securities mentioned in this document (or in any related investment) and may from time to time add to or dispose of any such securities (or investment). HSBC and its affiliates may have assumed an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis and may also perform or seek to perform investment banking or underwriting services for or relating to those companies and may also be represented in the supervisory board or any other committee of those companies.

The information and opinions contained within the research reports are based upon rates of taxation applicable at the time of publication but which are subject to change from time to time. Past performance is not necessarily a guide to future performance. The value of any investment or income may go down as well as up and you may not get back the full amount invested. Where an investment is denominated in a currency other than the local currency of the recipient of the research report, changes in the exchange rates may have an adverse effect on the value, price or income of that investment. In case of investments for which there is no recognised market it may be difficult for investors to sell their investments or to obtain reliable information about its value or the extent of the risk to which it is exposed.

HSBC Securities (USA) Inc. accepts responsibility for the content of this research report prepared by its non-US foreign affiliate. The information contained herein is under no circumstances to be construed as investment advice and is not tailored to the needs of the recipient. All US persons receiving and/or accessing this report and wishing to effect transactions in any security discussed herein should do so with HSBC Securities (USA) Inc. in the United States and not with its non-US foreign affiliate, the issuer of this report.

In the UK, this publication is distributed by HSBC Bank plc for the information of its Clients (as defined in the Rules of FCA) and those of its affiliates only. Nothing herein excludes or restricts any duty or liability to a customer which HSBC Bank plc has under the Financial Services and Markets Act 2000 or under the Rules of FCA and PRA. A recipient who chooses to deal with any person who is not a representative of HSBC Bank plc in the UK will not enjoy the protections afforded by the UK regulatory regime. HSBC Bank plc is regulated by the Financial Conduct Authority and the Prudential Regulation Authority. In Singapore, this publication is distributed by The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch for the general information of institutional investors or other persons specified in Sections 274 and 304 of the Securities and Futures Act (Chapter 289) ("SFA") and accredited investors and other persons in accordance with the conditions specified in Sections 275 and 305 of the SFA. Only Economics or Currencies reports are intended for distribution to a person who is not an Accredited Investor, Expert Investor or Institutional Investor as defined in SFA. The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch accepts legal responsibility for the contents of reports. This publication is not a prospectus as defined in the SFA. This publication is not a prospectus as defined in the SFA. It may not be further distributed in whole or in part for any purpose. The Hongkong and Shanghai Banking Corporation Limited Singapore Branch is regulated by the Monetary Authority of Singapore. Recipients in Singapore should contact a "Hongkong and Shanghai Banking Corporation Limited, Singapore Branch" representative in respect of any matters arising from, or in connection with this report. Please refer to The Hongkong and Shanghai Banking Corporation Limited Singapore Branch's website at www.business.hsbc.com.sg for contact details. In Canada, this publication may be distributed by HSBC Securities (Canada) Inc for the information of its customers only. All inquiries by such recipients must be directed to HSBC Securities (Canada) Inc. In Australia, this publication may be distributed by HSBC Stockbroking (Australia) Pty Limited. In Malaysia, this publication may be distributed by HSBC Research (Malaysia) Sdn Bhd. In Korea, this publication is distributed by either The Hongkong and Shanghai Banking Corporation Limited, Seoul Securities Branch ("HBAP SLS") or The Hongkong and Shanghai Banking Corporation Limited, Seoul Branch ("HBAP SEL") for the general information of professional investors specified in Article 9 of the Financial Investment Services and Capital Markets Act ("FSCMA"). This publication is not a prospectus as defined in the FSCMA. It may not be further distributed in whole or in part for any purpose. Both HBAP SLS and HBAP SEL are regulated by the Financial Services Commission and the Financial Supervisory Service of Korea. This publication is distributed in New Zealand by The Hongkong and Shanghai Banking Corporation Limited, New Zealand Branch incorporated in Hong Kong SAR. In Japan, this publication may be distributed by HSBC Securities (Japan) Limited. It may not be reproduced or further distributed in whole or in part for any purpose.

In the European Economic Area, this publication has been distributed by HSBC Continental Europe or by such other HSBC affiliate from which the recipient receives relevant services. In Australia, this publication has been distributed by The Hongkong and Shanghai Banking Corporation Limited (ABN 65 117 925 970, AFSL 301737) for the general information of its "wholesale" customers (as defined in the Corporations Act 2001). Where distributed to retail customers, this research is distributed by HSBC Bank Australia Limited (ABN 48 006 434 162, AFSL No. 232595). These respective entities make no representations that the products or services mentioned in this document are available to persons in Australia or are necessarily suitable for any particular person or appropriate in accordance with local law. No consideration has been given to the particular investment objectives, financial situation or particular needs of any recipient.

In Canada, this document has been distributed by HSBC Securities (Canada) Inc. (member IIROC), and/or its affiliates. The information contained herein is under no circumstances to be construed as investment advice in any province or territory of Canada and is not tailored to the needs of the recipient. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed judgment upon these materials, the information contained herein or the merits of the securities described herein, and any representation to the contrary is an offense. In Brazil, this document has been distributed by Banco HSBC SA ("HSBC Brazil"), and/or its affiliates. As required by Resolution No. 20/2021 of the Securities and Exchange Commission of Brazil (Comissão de Valores Mobiliários), potential conflicts of interest concerning (i) HSBC Brazil and/or its affiliates; and (ii) the analyst(s) responsible for authoring this report are stated on the chart above labelled "HSBC & Analyst Disclosures".

This communication is only intended for investment professionals within Article 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005. Persons who do not have professional experience in matters relating to investments should not rely on it. HSBC Yatırım Menkul Degerler A.S. is regulated and authorised by the Capital Markets Board of Türkiye and is a member of Borsa Istanbul AS.

If you are a customer of HSBC Wealth & Personal Banking ("WPB"), including Global Private Banking, you are eligible to receive this publication only if: (i) you have been approved to receive relevant research publications by an applicable HSBC legal entity; (ii) you have agreed to the applicable HSBC entity's terms and conditions and/or customer declaration for accessing research; and (iii) you have agreed to the terms and conditions of any other internet banking, online banking, mobile banking and/or investment services offered by that HSBC entity, through which you will access research publications (collectively with (ii), the "Terms"). If you do not meet the above eligibility requirements, please disregard this publication and, if you are a WPB customer, please notify your Relationship Manager or call the relevant customer hotline. Distribution of this publication is the sole responsibility of the HSBC entity with whom you have agreed the Terms. Receipt of research publications is strictly subject to the Terms and any other conditions or disclaimers applicable to the provision of the publications that may be advised by WPB.

© Copyright 2024, HSBC Yatirim Menkul Degerler AS, ALL RIGHTS RESERVED. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, on any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of HSBC. MCI (P) 017/01/2023, MCI (P) 061/09/2023, MCI (P) 073/10/2023, MCI (P) 007/10/2023